Home  »  Industry   »  Is Atara Biotherapeutics Inc. (NASDAQ:ATRA) Worth ...

Is Atara Biotherapeutics Inc. (NASDAQ:ATRA) Worth A Bite? ATRA 200 SMA stands at -17.24%

Atara Biotherapeutics Inc. (NASDAQ:ATRA) Relative Strength Index (RSI) is 45.65, with weekly volatility at 4.84% and ATR at 0.77. The ATRA stock’s 52-week price range has touched low of $8.90 and a $28.20 high. Intraday shares traded counted 0.6 million, which was 37.75% higher than its 30-day average trading volume of 956.55K. Its shares traded higher over the last trading session, gaining 2.95% on 05/26/21. The shares fell to a low of $13.27 before closing at $13.62. ATRA’s previous close was $13.23 while the outstanding shares total 91.46M. The firm has a beta of 2.39.

Investors have identified the Biotechnology company Atara Biotherapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.19 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Atara Biotherapeutics Inc. (ATRA) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 464.31 million total, with 84.19 million as their total liabilities.

ATRA were able to record -67.89 million as free cash flow during the 08/09/2021 quarter of the year, this saw their quarterly net cash flow reduce by -49.31 million. In cash movements, the company had a total of -65.7 million as operating cash flow.

Potential earnings growth for Atara Biotherapeutics Inc. (ATRA)

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 3.55 million trying to sell their products during the last quarter, with the result yielding a gross income of 81.8 million. This allows shareholders to hold on to 91.46M with the recently reported earning now reading -0.86 cents per share. This is a figure that compared to analyst’s prediction for their 08/09/2021 (-0.86 cents a share).

Having a look at the company’s valuation, the company is expected to record -3.47 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ATRA sounds very interesting.

Is the stock of ATRA attractive?

In related news, Chief Operations Officer, Newell Joe sold 2,453 shares of the company’s stock in a transaction that recorded on May 18. The sale was performed at an average price of 14.55, for a total value of 35,691. As the sale deal closes, the EVP, Head of R&D, Dupont Jakob now sold 5,184 shares of the company’s stock, valued at 75,427. Also, President and CEO, Touchon Pascal sold 8,313 shares of the company’s stock in a deal that was recorded on May 18. The shares were price at an average price of 14.55 per share, with a total market value of 120,954. Following this completion of acquisition, the SVP, GC & Secretary, Murugan Amar now holds 5,681 shares of the company’s stock, valued at 82,659. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.10%.

Leave a Comment

Your email address will not be published. Required fields are marked *